Russo Domenico, Battaglia Yuri
Department of Nephrology, School of Medicine, University Federico II, Via Pansini 5, 80131 Napoli, Italy.
Int J Nephrol. 2011;2011:364890. doi: 10.4061/2011/364890. Epub 2011 Apr 26.
FGF23 is a bone-derived hormone that plays an important role in the regulation of phosphate and 1,25-dihydroxy vitamin D metabolism. FGF23 principally acts in the kidney to induce urinary phosphate excretion and suppress 1,25-dihydroxyvitamin D synthesis in the presence of FGF receptor 1 (FGFR1) and its coreceptor Klotho. In patients with chronic kidney disease (CKD), circulating FGF23 levels are progressively increased to compensate for persistent phosphate retention, but this results in reduced renal production of 1,25-dihydroxyvitamin D and leads to hypersecretion of parathyroid hormone. Furthermore, FGF23 is associated with vascular dysfunction, atherosclerosis, and left ventricular hypertrophy. This paper summarizes the role of FGF23 in the pathogenesis of mineral, bone, and cadiovascular disorders in CKD.
成纤维细胞生长因子23（FGF23）是一种骨源性激素，在调节磷酸盐和1,25 - 二羟基维生素D代谢中起重要作用。FGF23主要作用于肾脏，在存在成纤维细胞生长因子受体1（FGFR1）及其共受体Klotho的情况下，诱导尿磷排泄并抑制1,25 - 二羟基维生素D的合成。在慢性肾脏病（CKD）患者中，循环中的FGF23水平逐渐升高以代偿持续的磷潴留，但这会导致肾脏1,25 - 二羟基维生素D生成减少，并导致甲状旁腺激素分泌过多。此外，FGF23与血管功能障碍、动脉粥样硬化和左心室肥厚有关。本文总结了FGF23在CKD矿物质、骨和心血管疾病发病机制中的作用。
